Parabilis Q2 EPS Miss Doesn't Deter Ra Capital Buying
Parabilis Medicines reported a Q2 EPS of -$2.12, missing consensus by 772.6% on zero trailing revenue. Despite this, Ra Capital—which invested $394 million at the IPO—has continued buying shares at hi
Ra Capital Bets $394M on Parabilis as Q2 Burns Deepen
NEW YORK, September 6 —
Parabilis Medicines, Inc. (PBLS) reported a Q2 2026 EPS of -$2.12 against a consensus estimate of -$0.24, a 772.6% miss, on a company with zero trailing revenue, yet the stock sits at $40.42, double the IPO price at which Ra Capital Management committed $394 million three months ago. The question hanging over a $4.99 billion valuation is whether Ra Capital's continued open-market buying is informed conviction or sunk-cost anchoring.
- Q2 EPS of -$2.12, a 772.6% miss vs. consensus -$0.24, per the August 13 8-K
- $1.12B cash vs. $0.05B debt; operating cash burn of -$111M on a trailing twelve-month basis
- $441M in total net insider buying across all Form 4 filings, zero insider sales reported
The Burn Rate Is Real, but the Accounting Matters
Parabilis, a Cambridge-based clinical-stage biotech founded in 2015 with roughly 145 employees, is building a pipeline around its Helicon platform, a system that generates stabilized helical peptides capable of hitting proteins historically considered undruggable, including intracellular protein-protein interactions. Its lead program, FOG-001, is a beta-catenin inhibitor targeting the TCF pathway in cancer. None of this generates revenue yet. The $111 million trailing cash burn is real, but an IPO quarter frequently front-loads non-cash compensation, underwriting costs, and one-time charges that collapse reported EPS far below any normalized run-rate. The 772.6% miss is alarming on its face; whether it represents an acceleration in underlying burn or a one-time accounting event is what the August 13 earnings 8-K leaves for investors to parse.
Ra Capital Kept Buying After the IPO Pop
Ra Capital Management purchased approximately 21.19 million shares at $20.00 on June 11, 2026, an IPO-related transaction totaling roughly $423.78 million per Form 4 filings. That alone would be unremarkable; anchor investors routinely take large IPO allocations. What is harder to dismiss is what came next: between July 20 and July 22, Ra returned to the open market six times, buying an additional 244,593 shares at prices ranging from $27.13 to $30.00. Those purchases carry no allocation obligation and no lock-up incentive, they are discretionary bets made after the stock had already risen 35-50% from the IPO price. Guy Levy added $10 million at the IPO as well. With $1.12 billion in cash against $50 million in debt, Parabilis has runway, and Ra appears to believe the burn is manageable relative to what FOG-001's data could be worth.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| PBLS | $5.0B | n/a | +27.9% |
| KLRA | $2.1B | n/a | -37.6% |
| COAG | $2.1B | n/a | +30.6% |
| EIKN | $588M | n/a | -27.6% |
| AVLN | $1.7B | n/a | +26.8% |
| MANE | $4.1B | n/a | +161.0% |
What to Watch Before Taking a Position
The entire thesis for PBLS resolves on undisclosed clinical outcomes. At $40.42 against a consensus price target of $41.75, the stock is priced to where analysts think it belongs today, before any data readout. The number that changes the calculus is the normalized quarterly cash burn stripped of IPO-related charges; if the underlying rate is materially higher than the trailing $111 million annualized figure, the $1.12 billion cash position buys fewer years of runway than the current valuation implies. The next catalyst is FOG-001 clinical updates, which will either validate Ra Capital's extraordinary conviction or expose it. Track Parabilis Medicines, Inc.'s latest numbers at Basis Report.
Current fundamentals, valuation and filing history for Parabilis Medicines, Inc. (PBLS) are tracked on its Basis Report page.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Why did Parabilis stock double after the IPO?
Parabilis is a clinical-stage biotech with no trailing revenue, but Ra Capital's continued buying, both at the IPO ($20 per share) and in the open market at higher prices, signaled confidence in FOG-001, its lead cancer program. The stock now sits at $40.42, double the IPO price.
How much cash burn does Parabilis have?
Parabilis reported operating cash burn of $111 million on a trailing twelve-month basis against $1.12 billion in cash and $50 million in debt. The Q2 EPS miss of -$2.12 versus consensus -$0.24 may include one-time IPO charges that don't reflect the underlying burn rate.
What is FOG-001?
FOG-001 is Parabilis' lead program, a beta-catenin inhibitor targeting the TCF pathway in cancer. The company's Helicon platform generates stabilized helical peptides capable of hitting proteins historically considered undruggable. FOG-001 clinical updates are the next catalyst that will validate or undermine Ra Capital's investment thesis.
How much did Ra Capital invest in Parabilis?
Ra Capital purchased 21.19 million shares at $20 per share on June 11, 2026 ($423.78 million total) as the IPO anchor investor. It then returned to the open market six times between July 20-22, buying 244,593 additional shares at $27.13 to $30.00 per share, discretionary purchases with no lock-up incentive.
What will determine Parabilis' valuation going forward?
The key metric is the normalized quarterly cash burn stripped of one-time IPO charges; if underlying burn is materially higher than the trailing $111 million annual rate, the $1.12 billion cash gives fewer years of runway than the current $4.99 billion valuation implies. The next catalyst is FOG-001 clinical data.
Parabilis Medicines reported a Q2 2026 EPS miss of 772.6%, with actual losses far exceeding analyst estimates, yet the stock now trades at $40.42 — well above the $20.00 per-share price at which Ra Capital Management committed approximately $394 million at the June IPO. A new $9.58 million stake from ICONIQ Capital signals institutional conviction is still building three months after the offering.